Varadha Balaji Venkadakrishnan

Varadha Balaji Venkadakrishnan

Auto-generated profile, based on publicly available information

Varadha Balaji Venkadakrishnan

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2023 in Nature Cancer
Verified
Journal Article
Closed access
PDF file
Martin K. BakhtMartin K. Bakht
Martin K. Bakht
YYYasutaka Yamada
Yasutaka Yamada
SKSheng-Yu Ku
Sheng-Yu Ku
VVVaradha Balaji Venkadakrishnan
Varadha Balaji Venkadakrishnan
JKJoshua A. Korsen
Joshua A. Korsen
HBHimisha Beltran
Himisha Beltran

8 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
VVVaradha Balaji Venkadakrishnan
Varadha Balaji Venkadakrishnan
APAdam G. Presser
Adam G. Presser
RSRicha Singh
Richa Singh
MBMatthew A. Booker
Matthew A. Booker
NTNicole A. Traphagen
Nicole A. Traphagen
HBHimisha Beltran
Himisha Beltran
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase and emerging therapeutic target that is overexpressed in most castration-resistant prostate cancers and implicated as a driver of disease progression and resistance to hormonal therapies. Here we define the lineage-specific action and differential activity of EZH2 in both prostate adenocarcinoma and neuroendocrine prostate cancer (NEPC) subtypes of advanced prostate cancer to better understand the role of EZH2 in modulating differentiation, lineage plasticity, and to identify mediators of response and resistance to EZH2 inhibitor therapy. Mechanistically, EZH2 modulates bivalent genes that results in upregulation of NEPC-associated transcriptional drivers (e.g., ASCL1) and neuronal gene programs in NEPC, and leads to forward differentiation after targeting EZH2 in NEPC. Subtype-specific downstream effects of EZH2 inhibition on cell cycle genes support the potential rationale for co-targeting cyclin/CDK to overcome resistance to EZH2 inhibition.

15 November 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
YYYasutaka Yamada
Yasutaka Yamada
VVVaradha Balaji Venkadakrishnan
Varadha Balaji Venkadakrishnan
KMKei Mizuno
Kei Mizuno
Martin K. BakhtMartin K. Bakht
Martin K. Bakht
SKSheng-Yu Ku
Sheng-Yu Ku
HBHimisha Beltran
Himisha Beltran
Aberrant DNA methylation has been implicated as a key driver of prostate cancer lineage plasticity and histologic transformation to neuroendocrine prostate cancer (NEPC). DNA methyltransferases (DNMTs) are highly expressed, and global DNA methylation is dysregulated in NEPC. We identified that deletion of DNMT genes decreases expression of neuroendocrine lineage markers and substantially reduced NEPC tumor development and metastasis in vivo. Decitabine, a pan-DNMT inhibitor, attenuated tumor growth in NEPC patient–derived xenograft models, as well as retinoblastoma gene ( RB1 )–deficient castration-resistant prostate adenocarcinoma (CRPC) models compared with RB1 -proficient CRPC. We further found that DNMT inhibition increased expression of B7 homolog 3 (B7-H3), an emerging druggable target, via demethylation of B7-H3. We tested DS-7300a (i-DXd), an antibody-drug conjugate targeting B7-H3, alone and in combination with decitabine in models of advanced prostate cancer. There was potent single-agent antitumor activity of DS-7300a in both CRPC and NEPC bearing high expression of B7-H3. In B7-H3–low models, combination therapy of decitabine plus DS-7300a resulted in enhanced response. DNMT inhibition may therefore be a promising therapeutic target for NEPC and RB1-deficient CRPC and may sensitize B7-H3–low prostate cancer to DS-7300a through increasing target expression. NEPC and RB1-deficient CRPC represent prostate cancer subgroups with poor prognosis, and the development of biomarker-driven therapeutic strategies for these populations may ultimately help improve patient outcomes.

18 July 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SKSheng-Yu Ku
Sheng-Yu Ku
YWYanqing Wang
Yanqing Wang
MGMaria Mica Garcia
Maria Mica Garcia
YYYasutaka Yamada
Yasutaka Yamada
KMKei Mizuno
Kei Mizuno
HBHimisha Beltran
Himisha Beltran
Notch signaling can have either an oncogenic or tumor-suppressive function in cancer depending on the cancer type and cellular context. While Notch can be oncogenic in early prostate cancer, we identified significant downregulation of the Notch pathway during prostate cancer progression from adenocarcinoma to neuroendocrine (NE) prostate cancer, where it functions as a tumor suppressor. Activation of Notch in NE and Rb1 / Trp53 -deficient prostate cancer models led to phenotypic conversion toward a more indolent, non-NE state with glandular features and expression of luminal lineage markers. This was accompanied by upregulation of MHC and type I IFN and immune cell infiltration. Overall, these data support Notch signaling as a suppressor of NE differentiation in advanced prostate cancer and provide insights into how Notch signaling influences lineage plasticity and the tumor microenvironment (TME).

1 April 2025 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
CBCristina Boixareu
Cristina Boixareu
TTTarek Taha
Tarek Taha
VVVaradha Balaji Venkadakrishnan
Varadha Balaji Venkadakrishnan
JBJohann de Bono
Johann de Bono
HBHimisha Beltran
Himisha Beltran

13 April 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
VVVaradha Balaji Venkadakrishnan
Varadha Balaji Venkadakrishnan
YYYasutaka Yamada
Yasutaka Yamada
KWKenny Weng
Kenny Weng
OIOsasenaga Idahor
Osasenaga Idahor
HBHimisha Beltran
Himisha Beltran
Cancer cells can undergo plasticity in response to environmental stimuli or under selective therapeutic pressures that result in changes in phenotype. This complex phenomenon of phenotypic plasticity is now recognized as a hallmark of cancer. Lineage plasticity is often associated with loss of dependence on the original oncogenic driver and is facilitated, in part, by underlying genomic and epigenetic alterations. Understanding the molecular drivers of cancer plasticity is critical for the development of novel therapeutic strategies. The retinoblastoma gene RB1 (encoding RB) is the first tumor suppressor gene to be discovered and has a well-described role in cell-cycle regulation. RB is also involved in diverse cellular functions beyond cell cycle including differentiation. Here, we describe the emerging role of RB loss in unlocking cancer phenotypic plasticity and driving therapy resistance across cancer types. We highlight parallels in cancer with the noncanonical role of RB that is critical for normal development and lineage specification, and the downstream consequences of RB loss including epigenetic reprogramming and chromatin reorganization that can lead to changes in lineage program. Finally, we discuss potential therapeutic approaches geared toward RB loss cancers undergoing lineage reprogramming.